A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17-Beta-Estradiol 1 mg, Drospirenone 2 mg /17-Beta-Estradiol 1 mg, Drospirenone 1 mg /17-Beta-Estradiol 1 mg) Combinations and 17-Beta-Estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension.

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17-Beta-Estradiol 1 mg, Drospirenone 2 mg /17-Beta-Estradiol 1 mg, Drospirenone 1 mg /17-Beta-Estradiol 1 mg) Combinations and 17-Beta-Estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2014

At a glance

  • Drugs Estradiol/drospirenone (Primary)
  • Indications Essential hypertension; Hot flashes; Menopause
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.
  • Most Recent Events

    • 03 Mar 2009 Actual patient numbers (1879) added as reported by ClinicalTrials.gov.
    • 03 Mar 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 08 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top